Synergy of Immunostimulatory Genetherapy with Immune Checkpoint Blockade Motivates Immune Response to Eliminate Cancer

A review of cancer immunotherapy toxicity

(2020) Lucy Boyce Kennedy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Time to dissect the autoimmune etiology of cancer antibody immunotherapy

(2020) Michael Dougan et al.   JOURNAL OF CLINICAL INVESTIGATION

Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges

(2020) John D. Martin et al.   Nature Reviews Clinical Oncology

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer

(2020) Kuan-Wei Huang et al.   Science Advances

Immunotherapy, Inflammation and Colorectal Cancer

(2020) Charles Robert Lichtenstern et al.   Cells

Acquired Resistance to Immune Checkpoint Inhibitors

(2020) Adam J. Schoenfeld et al.   CANCER CELL

Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma

(2020) Emilien Loeuillard et al.   JOURNAL OF CLINICAL INVESTIGATION

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

(2019) Xianjie Jiang et al.   Molecular Cancer

Immunotherapy in colorectal cancer: rationale, challenges and potential

(2019) Karuna Ganesh et al.   Nature Reviews Gastroenterology & Hepatology

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells

(2019) Hongwei Du et al.   CANCER CELL

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

(2019) A B Schrock et al.   ANNALS OF ONCOLOGY

Macrophages and Metabolism in the Tumor Microenvironment

(2019) Ilio Vitale et al.   Cell Metabolism

Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ

(2019) Chang Liu et al.   IMMUNITY

Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

(2019) Kloten et al.   Cells

Effects of interleukin-2 in immunostimulation and immunosuppression

(2019) Jonathan G. Pol et al.   JOURNAL OF EXPERIMENTAL MEDICINE

An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy

(2019) Lu Lu et al.   BIOMATERIALS

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

(2018) Krijn K. Dijkstra et al.   CELL

The great escape: how cationic polyplexes overcome the endosomal barrier

(2018) Tanja Bus et al.   Journal of Materials Chemistry B

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

Targeting macrophages: therapeutic approaches in cancer

(2018) Luca Cassetta et al.   NATURE REVIEWS DRUG DISCOVERY

Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression

(2017) Yu Zhu et al.   IMMUNITY

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

(2017) David J. Byun et al.   Nature Reviews Endocrinology

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Emerging targets in cancer immunotherapy

(2017) Samantha Burugu et al.   SEMINARS IN CANCER BIOLOGY

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

(2017) Janet Lau et al.   Nature Communications

Exploring the Role of RGD-Recognizing Integrins in Cancer

(2017) Markus Nieberler et al.   Cancers

Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target

(2016) Michael T. Werner et al.   BLOOD

Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape

(2016) Malte Mohme et al.   Nature Reviews Clinical Oncology

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Integrin αvβ3 Drives Slug Activation and Stemness in the Pregnant and Neoplastic Mammary Gland

(2014) Jay S. Desgrosellier et al.   DEVELOPMENTAL CELL

Non-viral vectors for gene-based therapy

(2014) Hao Yin et al.   NATURE REVIEWS GENETICS

Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity

(2013) Aleksandra M. Dudek et al.   Frontiers in Immunology

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progression

(2009) Jay S Desgrosellier et al.   NATURE MEDICINE